Heilongjiang University of Chinese Medicine, No.24, Xiangfang District.
First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Haerbin, Heilongjiang, China.
Medicine (Baltimore). 2021 Jan 22;100(3):e23903. doi: 10.1097/MD.0000000000023903.
Obstructive sleep apnea (OSA) is significant public concern. Clinical practice indicates that Chinese medicine has certain therapeutic advantages, while there is a lack of evidence-based medicine support. The aim of this study is to synthesize related data to explore efficacy and safety of Chinese medicine for OSA.
Data in PubMed, Embase, Web of Science, CNKI, WanFang, VIP databases were comprehensively searched. All the randomized controlled trials (RCTs) in OSA children were identified, in which the effects of Chinese medicine on a range of outcomes were compared. The search had a deadline of January 1, 2020. Two investigators independently conducted data extraction and assessed the literature quality of the included studies. The Revman5.3 software was used for meta-analysis of the included literature.
The efficacy and safety of Chinese medicine for OSA were evaluated in terms of apnea hypopnea index (AHI, the average and lowest blood oxygen, the Epworth Sleep Scale [ESS], and adverse effects).
This study provides reliable evidence-based support for the clinical application of Chinese medicine for OSA.
CRD42020154864.
阻塞性睡眠呼吸暂停（OSA）是一个公众非常关注的问题。临床实践表明，中医药具有一定的治疗优势，但缺乏循证医学的支持。本研究旨在综合相关数据，探讨中医药治疗 OSA 的疗效和安全性。
全面检索 PubMed、Embase、Web of Science、CNKI、万方、维普数据库，纳入 OSA 患儿的随机对照试验（RCT），比较中医药对多种结局的影响。检索截止日期为 2020 年 1 月 1 日。两名研究者独立进行数据提取并评价纳入研究的文献质量。采用 Revman5.3 软件对纳入文献进行 meta 分析。
从呼吸暂停低通气指数（AHI、平均及最低血氧、Epworth 睡眠量表[ESS]和不良反应）方面评价中医药治疗 OSA 的疗效和安全性。
本研究为中医药治疗 OSA 的临床应用提供了可靠的循证医学依据。
PROSPERO 注册号：CRD42020154864。
